Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 100 90 0?
Displaying drugs 1326 - 1350 of 2145 in total
BREN-02 is a recombinant human homeoprotein Engrailed 1 (rhEN1).
Investigational
AV-0113 consists of IL-12 secreting dendritic cells loaded with autologous tumor lysate.
Investigational
AVB-001 is an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native human IL-2 cytokine
Investigational
ISP-001 consists of sleeping beauty transposon-engineered autologous plasmablasts for expression and delivery of alpha-L-iduronidase.
Investigational
Investigational
An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
Investigational
Matched Salts cas: … 6151-30-0
Investigational
NB-001 has been investigated for the treatment of Recurrent Herpes Labialis.
Investigational
BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell) for human use (rHSV2hGM-CSF).
Investigational
AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis B (CHB) viral infection.
Investigational
Investigational
Investigational
Investigational
LTI-03 is a caveolin-1 Scaffolding Domain 7-Mer
Investigational
HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.
Investigational
Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
Investigational
ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
Investigational
CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Investigational
ELX-02 is under investigation in clinical trial NCT03309605 (Phase 1 Study of ELX-02 in Healthy Adult Subjects).
Investigational
AT-001 is under investigation in clinical trial NCT03062384 (AT-001 for Long-term Preservation of Brain Health in Aging).
Investigational
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
Investigational
EF-022 is a modified version of vitamin D binding protein macrophage activator, with potential antineoplastic and anti-angiogenic activities.
Investigational
Investigational
VCN-01 is an investigational, genetically modified human adenovirus encoding human PH20.
Investigational
Investigational
Displaying drugs 1326 - 1350 of 2145 in total